Age, ischemic heart disease, and kidney dysfunction are important predictors of outcomes in patients with idiopathic pulmonary arterial hypertension (IPAH), a…
Articles by José Lopes, PhD
Activation of a molecule called PPAR-gamma may be a future strategy to prevent pulmonary arterial hypertension (PAH)Â and other cardiovascular/pulmonary…
Right ventricular function of the heart is the primary determining factor of survival in patients with pulmonary arterial hypertension…
Arena Pharmaceuticals’Â ralinepag reduced the risk of pulmonary arterial hypertension patients dying, a Phase 2 clinical trial showed.
Children with pulmonary hypertension (PH) are a relatively high-risk group for cardiac catheterization, a new study shows. In turn, hospital…
Bardoxolone methyl, Reata Pharmaceuticals’ treatment candidate for pulmonary hypertension (PH), improves exercise capacity and has a safe profile…
Combinations of Reviva Pharmaceuticals’ RP5063 and other pulmonary arterial hypertension treatments improved rats’  lung blood vessel structure and lung function, a…
Subcutaneous Remodulin (treprostinil), marketed by United Therapeutics, is to be safe and effective for at least 12 months in patients…
Treatment with Tracleer (bosentan) is effective in patients with pulmonary arterial hypertension (PAH), a new review study…
AIT Therapeutics has acquired a global, exclusive license from NitricGen for a new nitric oxide (NO) delivery system that may benefit newborns…
French scientists have identified antibodies that appear to increase the risk of a poor outcome in pulmonary arterial hypertension patients…
Important research findings, therapy advances, and other events related to pulmonary hypertension were reported daily in Pulmonary Hypertension News during 2017. Now…